Top

International Urology and Nephrology

Published in:

01-10-2018 | Nephrology - Review

The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis

Authors: Jing Sun, Hongjun Sun, Meiyu Cui, Zhijian Sun, Wenyue Li, Jianxin Wei, Shuhua Zhou

Published in: International Urology and Nephrology | Issue 10/2018

Abstract

Purpose

We conducted a meta-analysis to explore the association between the use of different anti-ulcer agents and the risk of chronic kidney disease (CKD), end-stage renal disease (ESRD), and decline in glomerular filtration rate (GFR) in various study populations.

Methods

PubMed, Embase, and the Cochrane Library were searched for relevant entries up to July 1, 2017. The primary outcomes of the meta-analysis were risk ratios (RRs) of CKD, ESRD, and decline in GFR. We also investigated the heterogeneity of the meta-analysis by subgroup analysis and meta-regression analysis.

Results

A total of 662,624 individuals were enrolled in five trials. Compared with non-PPI users, PPI users had a higher trend of CKD (RR = 1.16, 95% CI 1.07–1.25, P < 0.001), especially ESRD (RR = 1.81, 95% CI 1.59–2.06, P < 0.001). There was an elevated risk of adverse renal outcome among participants receiving PPI and not H2RA (CKD: RR = 1.28, 95% CI 1.24–1.33, P < 0.001; ESRD: RR = 1.39, 95% CI 1.17–1.64, P < 0.001; GFR: RR = 1.31, 95% CI 1.26–1.36, P < 0.001). However, H2RA users were not associated with CKD when compared with non-H2RA users (RR = 1.02, 95% CI 0.83–1.25, P = 0.855). In subgroup analysis, the average age of individuals and drug dosage had no influence on the risk of CKD, while duration of PPI exposure from 31 to 720 days is a potential factor in progression to ESRD (P < 0.001).

Conclusions

Chronic PPI use, but not H2RAs, is associated with deterioration in kidney function.

Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Abdelhamid YA, Anderson MB, Chapman MJ, Rayner CK, Deane AM (2016) Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP)): randomized double-blind exploratory study. Crit Care Med 44(10):1842–1850. https://doi.org/10.1097/ccm.0000000000001819 CrossRefPubMed

Alhazzani W, Guyatt G, Alshahrani M, Deane AM, Marshall JC, Hall R, Muscedere J, English SW, Lauzier F, Thabane L, Arabi YM, Karachi T, Rochwerg B, Finfer S, Daneman N, Alshamsi F, Zytaruk N, Heel-Ansdell D, Cook D (2017) Withholding pantoprazole for stress ulcer prophylaxis in critically ill patients: a pilot randomized clinical trial and meta-analysis. Crit Care Med 45(7):1121–1129. https://doi.org/10.1097/ccm.0000000000002461 CrossRefPubMed

El-Kersh K, Jalil B, McClave SA, Cavallazzi R, Guardiola J, Guilkey K, Persaud AK, Furmanek SP, Guinn BE, Wiemken TL, Alhariri BC, Kellie SP, Saad M (2017) Enteral nutrition as stress ulcer prophylaxis in critically ill patients: a randomized controlled exploratory study. J Crit Care 43:108–113. https://doi.org/10.1016/j.jcrc.2017.08.036 CrossRefPubMed

Wu H, Jing Q, Wang J, Guo X (2011) Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care 26(4):e431–e436. https://doi.org/10.1016/j.jcrc.2010.12.007 CrossRef

MacLaren R, Campbell J (2014) Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Crit Care Med 42(4):809–815CrossRefPubMed

Somberg L, Morris J Jr, Fantus R, Graepel J, Field BG, Lynn R, Karlstadt R (2008) Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric ph control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 64(5):1202–1210. https://doi.org/10.1097/TA.0b013e31815e40b5 CrossRefPubMed

Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H (2017) Association between proton pump inhibitors and hepatic encephalopathy: a meta-analysis. Medicine 96(17):e6723. https://doi.org/10.1097/md.0000000000006723 CrossRefPubMedPubMedCentral

Wang Y-F, Chen Y-T, Luo J-C, Chen T-J, Wu J-C, Wang S-J (2017) Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol 112(7):1084–1093. https://doi.org/10.1038/ajg.2017.101 CrossRefPubMed

Zhu W, Hong K (2017) Potential cardiovascular risks of proton pump inhibitors in the general population. Int Heart J 58(2):163–166CrossRefPubMed

10.

Harmark L, van der Wiel HE, de Groot MC, van Grootheest AC (2007) Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 64(6):819–823. https://doi.org/10.1111/j.1365-2125.2007.02927.x CrossRefPubMedPubMedCentral

11.

Moledina DG, Perazella MA (2017) Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol 60(2):804–817

12.

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176(2):238–246. https://doi.org/10.1001/jamainternmed.2015.7193 CrossRefPubMedPubMedCentral

13.

Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, Lohr JW (2016) Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 17(1):112. https://doi.org/10.1186/s12882-016-0325-4 CrossRefPubMedPubMedCentral

14.

Wells GA, Shea B, O’Connell D, Peterson J Welch V, Losos M, Tugwell P (2017) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 15 Mar 2017

15.

Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta analysis detected by a simple, graphical test. BMJ 315(7109):629–634CrossRefPubMedPubMedCentral

16.

Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, Paterson JM, Juurlink DN (2015) Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 3(2):E166–E171. https://doi.org/10.9778/cmajo.20140074 CrossRef

17.

Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, Hennessy S, Strom BL (2012) Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 21(11):1155–1172. https://doi.org/10.1002/pds.3329 CrossRefPubMed

18.

Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z (2016) Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 27(10):3153–3163. https://doi.org/10.1681/ASN.2015121377 CrossRefPubMedPubMedCentral

19.

Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z (2017) Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int 91(6):1482–1494. https://doi.org/10.1016/j.kint.2016.12.021 CrossRefPubMed

20.

Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, Wettermark B, Arnlov J, Janmaat CJ, Lindholm B, Dekker FW, Coresh J, Grams ME, Carrero JJ (2017) Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. https://doi.org/10.1053/j.gastro.2017.05.046 CrossRefPubMed

21.

Peng Y-C, Lin C-L, Yeh H-Z, Chang C-S, Wu Y-L, Kao C-H (2016) Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases. Medicine 95(15):e3363. https://doi.org/10.1097/md.0000000000003363 CrossRefPubMedPubMedCentral

22.

Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, Chongruksut W, Thavorn K (2017) The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfw470 CrossRef

23.

Yang Y, George KC, Shang W, Zeng R, Ge S, Xu G (2017) Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Dev Ther 11:1291–1299. https://doi.org/10.2147/dddt.s130568 CrossRef

24.

Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, Nasr SH (2015) Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 87(2):458–464. https://doi.org/10.1038/ki.2014.294 CrossRefPubMed

Title: The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis
Authors: Jing Sun
Hongjun Sun
Meiyu Cui
Zhijian Sun
Wenyue Li
Jianxin Wei
Shuhua Zhou
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 10/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1908-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2018

Prophylactic selective arterial embolization for renal angiomyolipomas: efficacy and evaluation of predictive factors of significant shrinkage

Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder

Is sodium thiosulfate an effective treatment for recurrent calcium nephrolithiasis? Pro and con arguments

Transplant nephrectomy after graft failure: is it so risky? Impact on morbidity, mortality and alloimmunization

Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?

An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page